News

Avanir Pharmaceuticals expects the FDA to classify the response as a Class 2 resubmission, which would result in an expected review period of 180 days and potential approval

Automaglia 90 Analyzer is a fully-automated analyzer for immunoassay analysis in various types of diseases and disorders. Major clinical diagnostic applications include thyroid disorders, fertility and infertility disorders,

The ANDA, which was developed and registered by Granules, is in collaboration with Heritage Pharmaceuticals, a generic pharmaceutical company. Under a previous agreement, Heritage retains exclusive sales and

Mnemonics said that the tool helps in inspecting multiple-page documents including batch inspection of labels, catalogs, instruction manuals, long manuscripts, magazines. Mnemonics claimed that AVIA Infinity makes proofreading

Dendreon plans to have three plants to make Provenge by mid of 2011. According to an estimate by Bloomberg the drug is expected to generate $1.2bn by 2014.

The approval is based on data from the pivotal SATURN study which showed that compared to placebo Tarceva gave patients with stable disease a 39% improvement in overall

NexMed claimed that the incorporation of NexAct enabled the dose of A6 to be cut by half, or from twice per day to once per day delivered subcutaneously,

As part of the joint venture agreement, Labopharm is expected to grant Angelini Labopharm the exclusive right to market and sell Oleptro in the US. The joint venture,

MWV has posted a net income of $24m for the first quarter of 2010, or $0.14 per diluted share, compared to net loss of $79m, or $0.46 per